Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BVX 130

Next Previous
Drug Profile

BVX 130

Alternative Names: BVX 130-monomethylauristatin E; BVX-130; BVX-130-MMAE; BVX130-maleimidocaproyl monomethylauristatin F; BVX130-mcMMAF

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BiVictriX Therapeutics
  • Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunotoxins
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (Parenteral)
  • 29 Jul 2020 BVX 130 is available for licensing as of 29 Jul 2020. 3492629
  • 22 Jun 2020 Preclinical trials in Acute myeloid leukaemia in United Kingdom (Parenteral), prior to June 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top